Gestor Editorial

Nuevo Usuario
Revisiones en Cáncer 00031 / http://dx.doi.org/10.20960/revcancer.00031
Resumen| PDF

Revisión

Tratamiento del cáncer de mama metastásico hormonosensible en primera línea

Ignacio Chacón López-Muñiz, Juan David Cárdenas, Irene Otero Blas

Prepublicado: 2023-07-12
Publicado: 2023-07-12
VOLUMEN 37, NÚM. 1, enero-febrero (2023), PAG. 30-37

Logo Descargas   Número de descargas: 49914      Logo Visitas   Número de visitas: 1308      Citas   Citas: 0

Compártelo:


Después de mucho tiempo sin novedades terapéuticas, desde hace unos 5 años el tratamiento de los cánceres de mama luminales metastásicos ha cambiado de forma sustancial. En la actualidad el estándar se basa en los inhibidores de las cinasas 4 y 6 dependientes de ciclina, los iCDK4/6: palbociclib, ribociclib, abemaciclib. Su incorporación a la primera línea, siempre combinados con tratamiento endocrino, (AI [letrozol, anastrozol, exemestano] o fulvestrant) ha modificado el pronóstico de estas pacientes, aumentando en todos los casos de forma significativa la supervivencia libre de progresión (PFS). El único que ha conseguido ampliar la supervivencia global (OS) ha sido el ribociclib. Sin embargo, se espera que el abemaciclib también lo haga cuando se produzcan los eventos necesarios. El palbociclib ha obtenido ventaja en la OS en los estudios de vida real, pero no en los ensayos clínicos. La toxicidad de los tres iCDK4/6 es similar, muy controlable y previsible, y se han convertido en el nuevo estándar de primera línea en los tumores luminales metastásicos.

Palabras Clave: Ribociclib. Palbociclib. Abemaciclib. Supervivencia global. Supervivencia libre de progresión. Hormonoterapia.



Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.
DOI: 10.3322/caac.21660
American Cancer Society. Breast Cancer Facts & Figures 2022-2024. Atlanta: American Cancer Society, Inc. 2022
Las cifras del cáncer en España 2022. Sociedad Española de Oncología Médica (SEOM). www.seom.org
Las cifras del cáncer en España 2023. Sociedad Española de Oncología Médica (SEOM). www.seom.org
Instituto Nacional de Estadística (INE). Defunciones según la causa de muerte. Disponible en: https://www.ine.es/jaxiT3/Tabla.htm?t=6609.
Cezary Wojtyla, Paola Bertuccio, Andrzej Wojtyla, Carlo La Vecchia. European trends in breast cancer mortality, 1980-2017 and predictions to 2025. European Journal of Cancer 152 (2021) 4-17.
Las Cifras del cáncer en España 2018. Sociedad española de Oncología Médica (SEOM). www.seom.org
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025patients diagnosed with one of 18 cancers from 322 population -basedregistries in 71 countries. Lancet. 2018;391(10125):1023-1075.
DOI: 10.1016/S0140-6736(17)33326-3
Malmgren JA, Mayer M, Atwood MK, et al. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010. Breast Cancer Res Treat. 2018;167(2):579-590.
DOI: 10.1007/s10549-017-4529-5
Linda Sofie Lindström, Eva Karlsson, Ulla M. Wilking, Ulla Johansson, Johan Hartman, Elisabet Kerstin Lidbrink, Thomas Hatschek, Lambert Skoog, and Jonas Bergh. Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression. Journal of Clinical Oncology 2012 30:21, 2601-2608.
DOI: 10.1200/JCO.2011.37.2482
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast Cancer, Version 4.2023 — March 23, 2023. NCCN.org
Eubank WB, Mankoff D, Bhattacharya M, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004; 183:479-486. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15269044.
DOI: 10.2214/ajr.183.2.1830479
Podoloff DA, Advani RH, Allred C, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007;5 Suppl 1:1-1. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17509259.
DOI: 10.6004/jnccn.2007.2001
Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007; 27Suppl 1:S215-229. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18180228.
DOI: 10.1148/rg.27si075517
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020;31(12):1623-1649.
DOI: 10.1016/j.annonc.2020.09.010
Lee CI, Gold LS, Nelson HD, et al. Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. Breast 2015;24(1):3-11.
DOI: 10.1016/j.breast.2014.11.009
Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014;23(5):489-502.
DOI: 10.1016/j.breast.2014.08.009
Harold J. Burstein, Mark R. Somerfield, Debra L. Barton, Ali Dorris, Lesley J. Fallowfield, Dharamvir Jain, Stephen R. D. Johnston, Larissa A. Korde, Jennifer K. Litton, Erin R. Macrae, Lindsay L. Peterson, Praveen Vikas, Rachel L. Yung, and Hope S. Rugo. Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology 2021; 39:35, 3959-3977
Llombart-Cussac A, Pérez-García JM, Bellet M, et al. PARSIFAL: a randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitivepatients with estrogen receptor (ER)[.]/HER2[-] metastatic breast cancer. J Clin Oncol. 2020; 38(15_suppl):1007.
DOI: 10.1200/JCO.2020.38.15_suppl.1007
Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021 Dec;32(12):1475-1495.
DOI: 10.1016/j.annonc.2021.09.019
Finn RS, Martin M, Rugo HS, et al: Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925-1936, 2016
DOI: 10.1056/NEJMoa1607303
Rugo HS, Finn RS, Dieras V, et al: Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 174:719-729, 2019.
DOI: 10.1007/s10549-018-05125-4
Richard S. Finn, Hope S. Rugo, Veronique C Dieras, Nadia Harbeck, Seock-Ah Im, Karen A. Gelmon, Janice Maria Walshe, Miguel Martin, Mariana Chavez Mac Gregor, Eustratios Bananis, Eric Roland Gauthier, Dongrui Ray Lu, Sindy Kim, and Dennis J. Slamon. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. Journal of Clinical Oncology 2022 40:17_suppl, LBA1003-LBA1003.
DOI: 10.1200/JCO.2022.40.17_suppl.LBA1003
Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ Breast Cancer. 2022 Oct 11;8(1):114.
DOI: 10.1038/s41523-022-00479-x
Rugo HS, Dieras V, Gelmon KA, et al: Impact of palbociclib plus letrozole on patient-reported health-related quality of life: Results from the PALOMA-2 trial. Ann Oncol 29:888-894, 2018.
DOI: 10.1093/annonc/mdy012
Goetz MP, Toi M, Campone M, et al: MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:3638-3646, 2017.
DOI: 10.1200/JCO.2017.75.6155
Johnston S, Martin M, Di Leo A, et al: MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5:5, 2019.
DOI: 10.1038/s41523-018-0097-z
M.P. Goetz, M. Toi, J. Huober, J. Sohn, O. Tredan, I.H. Park, M. Campone, S.C. Chen, L.M. Manso Sanche, S. Paluch-Shimon, G. van Hal, A. Shahi, H. Iwata, S. Johnston. LBA15 - MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). Annals of Oncology (2022) 33 (suppl_7): S808-S869. 10.1016/annonc/annonc1089.
Goetz MP, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Stoffregen C, Shekarriz S, Andre V, Gainford MC, Price GL, Johnston S. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. Oncologist 2020 Sep;25(9):e1346-e1354.
DOI: 10.1634/theoncologist.2020-0084
Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993.
DOI: 10.1093/jnci/85.5.365
Sprangers MA, Groenvold M, Arraras JI, et al: The European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality-of-Lifequestionnaire module: First results from a three-country field study. J Clin Oncol 14:2756-2768, 1996
DOI: 10.1200/JCO.1996.14.10.2756
Hortobagyi GN, Stemmer SM, Burris HA, et al: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738-1748, 2016.
DOI: 10.1056/NEJMoa1609709
O’Shaughnessy J, Petrakova K, Sonke GS, et al: Ribociclib plus letrozole versus letrozole alone in patients with de novo HR1, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat 168:127-134, 2018.
DOI: 10.1007/s10549-017-4518-8
Sonke GS, Hart LL, Campone M, et al: Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat 167:659-669, 2018.
DOI: 10.1007/s10549-017-4523-y
G.N. Hortobagyi, S.M. Stemmer, H.A. Burris III, Y.S. Yap, G.S. Sonke, L. Hart, M. Campone, K. Petrakova, E.P. Winer, W. Janni, P.F. Conte, D. Cameron, F. André, C. Arteaga, J.P. Zarate, A. Chakravartty, T. Taran, F. Le Gac, P. Serra, J. O'Shaughnessy. LBA17_PR - Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB). Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741
Hortobagyi GN, Stemmer SM, Burris HA, et al: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29:1541-1547, 2018.
DOI: 10.1093/annonc/mdy155
Janni W, Alba E, Bachelot T, et al: First-line ribociclib plus letrozole in postmenopausal women with HR1, HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. Breast Cancer Res Treat 169:469-479, 2018.
DOI: 10.1007/s10549-017-4658-x
Verma S, O’Shaughnessy J, Burris HA, et al: Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib 1 letrozole: Results from MONALEESA-2. Breast Cancer Res Treat 170:535-545, 2018.
DOI: 10.1007/s10549-018-4769-z
Tripathy D, Im SA, Colleoni M, et al: Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomized phase 3 trial. Lancet Oncol 19:904-915, 2018
DOI: 10.1016/S1470-2045(18)30292-4
Im SA, Lu YS, Bardia A, et al: Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381:307-316, 2019.
DOI: 10.1056/NEJMoa1903765
Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, Harbeck N, Hurvitz S, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, O'Regan R, Gasch C, Solovieff N, Wang C, Wang Y, Chakravartty A, Ji Y, Tripathy D. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2022 Mar 1;28(5):851-859.
DOI: 10.1158/1078-0432.CCR-21-3032
Harbeck N, Franke F, Villanueva-Vazquez R, et al: Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: Results from a phase III randomized clinical trial (MONALEESA-7). Ther Adv Med Oncol12:1758835920943065, 2020
DOI: 10.1177/1758835920943065
Cocks K, King MT, Velikova G, et al. Quality, interpretation, and presentation of European Organization for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomized controlled trials. Eur J Cancer 2008; 44: 1793–1798.
DOI: 10.1016/j.ejca.2008.05.008
Ettl J, Im SA, Ro J, Masuda N, Colleoni M, Schnell P, Bananis E, Lu DR, Cristofanilli M, Rugo HS, Finn RS. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Res. 2020 Mar 12;22(1):27.
DOI: 10.1186/s13058-020-01263-0
Lu Y, Yang S, Ho YY, Ji Y. Ribociclib Population Pharmacokinetics and Pharmacokinetic/ Pharmacodynamic Analysis of Neutrophils in Cancer Patients. J Clin Pharmacol. 2021 Aug;61(8):1054-1068.
DOI: 10.1002/jcph.1856
J. Klastersky, J. de Naurois, K. Rolston, B. Rapoport, G. Maschmeyer, M. Aapro & J. Herrstedt on behalf of the ESMO Guidelines Committe*. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Annals of Oncology 27 (Supplement 5): v111–v118, 2016
Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, André VAM, Chouaki N, San Antonio B, Toi M, Sledge GW Jr. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Res Treat. 2021 Apr;186(2):417-428.
DOI: 10.1007/s10549-020-06029-y
Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018 Sep; 101:123-133.
DOI: 10.1016/j.ejca.2018.05.017
Burris, H.A., Chan, A., Bardia, A. et al. Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. Br J Cancer 125, 679–686 (2021). https://doi.org/10.1038/s41416-021-01415-9
DOI: 10.1038/s41416-021-01415-9

Revisión: Carcinoma localmente avanzado. Hormonoterapia neoadyuvante en cáncer de mama con expresión de receptores hormonales y HER2 negativo

Publicado: 2023-03-29 / http://dx.doi.org/
Resumen | PDF

Artículos más populares


Editado en Madrid por:
Diseño y Desarrollo web Im3diA comunicación

Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web. La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias. Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso. En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web. Más información en el apartado “POLÍTICA DE COOKIES” de nuestra página web.

Rechazar